What Is The Impact Of Age On Adult Patients With Inflammatory Bowel Disease?

Authors

  • Cristina Cijevski Prelipcean
  • Cătălina Mihai
  • Petruţ Gogălniceanu
  • Bogdan Mihai

Keywords:

elderly, diagnosis, inflammatory bowel disease, therapy, young adults

Abstract

     Inflammatory bowel disease (IBD) is a chronic disease that affects both young adults and also the elderly. This article emphasises the particularities related to age in the epidemiology, diagnosis, natural course of the disease, prognosis and therapy of adult patients with IBD. Even though the main characteristics in geriatric populations with IBD may not differ much from those in younger patients, distinct problems exist.
     The majority of IBD studies were performed on young subjects, younger than 40 years of age. The optimal therapeutic choice in young individuals with IBD is a challenge for the physician who needs to take in account the risk of untreated or suboptimally treated chronic intestinal inflammation, long term prognosis, quality of life, the impact of side-effects of aggressive therapeutic approaches, the impact on pregnancy, as well as personal and healthcare costs. 

     The diagnosis in elderly patients can be challenging due to the large number of conditions that mimic IBD. The treatment options are those used in younger patients, but a series of considerations related to potential pharmacological interactions and side effects of the drugs must be taken in account. The risks associated with the use of some IBD medications may be increased in older patients, but so is the risk of under-treated IBD and surgery.

Author Biography

Cristina Cijevski Prelipcean, University of Medicine and Pharmacy “Gr. T. Popa”, Iași, Romania Center of Gastroenterology and Hepatology, University Hospital “Sf. Spiridon” Iaşi, Romania

bio

Downloads

Published

2014-02-14

How to Cite

1.
Cijevski Prelipcean C, Mihai C, Gogălniceanu P, Mihai B. What Is The Impact Of Age On Adult Patients With Inflammatory Bowel Disease?. Med Pharm Rep [Internet]. 2014 Feb. 14 [cited 2025 Oct. 6];86(1):3-9. Available from: https://medpharmareports.com/index.php/mpr/article/view/98

Issue

Section

Reviews